Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival

References

• Cristofanilli M, Buchholz TA. Proceedings of the First International Inflammatory Breast Cancer Conference. Cancer 2010;116:S2729
   PubMedGoogle Scholar
• Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, et al. International expert panel on inflammatory breast cancer: Consensus statement for standardized diagnosis and treatment. Ann Oncol 2011;22:515–23
   PubMed Web of Science ®Google Scholar
• Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, et al. Inflammatory breast cancer: The disease, the biology, the treatment. CA Cancer J Clin 2010;60:351–75
   PubMed Web of Science ®Google Scholar
• Vujaskovic Z, Kim DW, Jones E, Lan L, McCall L, Dewhirst MW, et al. A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia 2010;26:514–21
   PubMed Web of Science ®Google Scholar
• Oh DS, Cheang MC, Fan C, Perou CM. Radiation-induced gene signature predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. Radiat Res 2014;181:193–207
   PubMed Web of Science ®Google Scholar
• Dressman HK, Hans C, Bild A, Olson JA, Rosen E, Marcom PK, et al. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 2006;12:819–26
   PubMed Web of Science ®Google Scholar
• Craciunescu OI, Blackwell KL, Jones EL, Macfall JR, Yu D, Vujaskovic Z, et al. DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: A pilot study. Int J Hyperthermia 2009;25:405–15
   PubMed Web of Science ®Google Scholar
• Kuhl CK, Schild HH. Dynamic image interpretation of MRI of the breast. J Magn Reson Imaging 2000;12:965–74
   PubMedGoogle Scholar
• Daniel BL, Yen YF, Glover GH, Ikeda DM, Birdwell RL, Sawyer-Glover AM, et al. Breast disease: Dynamic spiral MR imaging. Radiology 1998;209:499–509
   PubMedGoogle Scholar
• Helbich TH. Contrast-enhanced magnetic resonance imaging of the breast. Eur J Radiol 2000;34:208–19
   PubMed Web of Science ®Google Scholar
• Moeller BJ, Dewhirst MW. Raising the bar: How HIF-1 helps determine tumor radiosensitivity. Cell Cycle 2004;3:1107–10
   PubMed Web of Science ®Google Scholar
• Craciunescu OI, Thrall DE, Vujaskovic Z, Dewhirst MW. Magnetic resonance imaging: A potential tool in assessing the addition of hyperthermia to neoadjuvant therapy in patients with locally advanced breast cancer. Int J Hyperthermia 2010;26:625–37
   PubMed Web of Science ®Google Scholar
• Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: Archive for functional genomics data sets – Update. Nucleic Acids Res 2013;41:D991–5
   PubMed Web of Science ®Google Scholar
• Gentleman R. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. New York: Springer Science+Business Media; 2005
   Google Scholar
• Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80
   PubMed Web of Science ®Google Scholar
• Owzar K, Barry WT, Jung SH. Statistical considerations for analysis of microarray experiments. Clin Transl Sci 2011;4:466–77
   PubMedGoogle Scholar
• Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15
   PubMed Web of Science ®Google Scholar
• Mardia KV, Kent JT, Bibby JM. Multivariate Analysis. London-New York-Toronto-Sydney-San Francisco: Academic Press, 1979
   Google Scholar
• Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982;69:239–41
   Web of Science ®Google Scholar
• Hothorn T, Hornik K, Zeileis A. Unbiased recursive partitioning: A conditional inference framework. J Comput Graph Stat 2006;15:651–74
   Web of Science ®Google Scholar
• Comprehensive molecular portraits of human breast tumours. Nature 2012 10/04/print;490(7418):61--70
   PubMed Web of Science ®Google Scholar
• Viglianti BL, Lora-Michiels M, Poulson JM, Lan L, Yu D, Sanders L, et al. Dynamic contrast-enhanced magnetic resonance imaging as a predictor of clinical outcome in canine spontaneous soft tissue sarcomas treated with thermoradiotherapy. Clin Cancer Res 2009;15:4993–5001
   PubMed Web of Science ®Google Scholar
• Losordo DW, Isner JM. Estrogen and angiogenesis: A review. Arterioscler Thromb Vasc Biol 2001;21:6–12
   PubMed Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. The Lancet 2010 Jul 24;376(9737):235–44
   PubMedGoogle Scholar
• Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res 2013;15:R88
   PubMed Web of Science ®Google Scholar
• Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, et al. Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. J Nucl Med 2013;54:913–21
   PubMed Web of Science ®Google Scholar
• Bundred N, Gardovskis J, Jaskiewicz J, Eglitis J, Paramonov V, McCormack P, et al. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: A phase I multicentre trial in patients scheduled for elective breast cancer surgery. Invest New Drugs 2013;31:949–58
   PubMed Web of Science ®Google Scholar
• Janzen DM, Paik DY, Rosales MA, Yep B, Cheng D, Witte ON, et al. Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo. Mol Cancer Ther 2013;12:2917–28
   PubMed Web of Science ®Google Scholar
• Toh Y, Kuwano H, Mori M, Nicolson GL, Sugimachi K. Overexpression of metastasis-associated MTA1 mRNA in invasive oesophageal carcinomas. Br J Cancer 1999;79:1723–6
   PubMedGoogle Scholar
• Giannini R, Cavallini A. Expression analysis of a subset of coregulators and three nuclear receptors in human colorectal carcinoma. Anticancer Res 2005;25:B4287–92
   PubMed Web of Science ®Google Scholar
• Kidd M, Modlin IM, Mane SM, Camp RL, Eick G, Latich I. The role of genetic markers – NAP1L1, MAGE-D2, and MTA1 – in defining small-intestinal carcinoid neoplasia. Ann Surg Oncol 2006;13:253–62
   PubMed Web of Science ®Google Scholar
• Dannenmann C, Shabani N, Friese K, Jeschke U, Mylonas I, Bruning A. The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO. Cancer Biol Ther 2008;7:1460–7
   PubMedGoogle Scholar
• Hofer MD, Tapia C, Browne TJ, Mirlacher M, Sauter G, Rubin MA. Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue. Arch Pathol Lab Med 2006;130:989–96
   PubMed Web of Science ®Google Scholar
• Il’yasova D, Siamakpour-Reihani S, Akushevich I, Akushevich L, Spector N, Schildkraut J. What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma? Breast Cancer Res Treat 2011;130:691–7
   PubMed Web of Science ®Google Scholar
• Cooney CA, Jousheghany F, Yao-Borengasser A, Phanavanh B, Gomes T, Kieber-Emmons AM, et al. Chondroitin sulfates play a major role in breast cancer metastasis: A role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res 2011;13:R58
   PubMed Web of Science ®Google Scholar
• Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006;18:516–23
   PubMed Web of Science ®Google Scholar
• Golubovskaya VM, Cance W. Focal adhesion kinase and p53 signal transduction pathways in cancer. Front Biosci 2010;15:901–12
   PubMedGoogle Scholar
• Kinoshita T, Nohata N, Watanabe-Takano H, Yoshino H, Hidaka H, Fujimura L, et al. Actin-related protein 2/3 complex subunit 5 (ARPC5) contributes to cell migration and invasion and is directly regulated by tumor-suppressive microRNA-133a in head and neck squamous cell carcinoma. Int J Oncol 2012;40:1770–8
   Google Scholar
• Hancox RA, Allen MD, Holliday DL, Edwards DR, Pennington CJ, Guttery DS, et al. Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 2009;11:R24
   PubMed Web of Science ®Google Scholar
• Chae SW, Sohn JH, Kim DH, Choi YJ, Park YL, Kim K, et al. Overexpressions of Cyclin B1, cdc2, p16 and p53 in human breast cancer: The clinicopathologic correlations and prognostic implications. Yonsei Med J 2011;52:445–53
   PubMedGoogle Scholar
• Nouh M, Mohamed M, El-Shinawi M, Shaalan M, Cavallo-Medved D, Khaled H, et al. Cathepsin B: A potential prognostic marker for inflammatory breast cancer. J Transl Med 2011;9:1
   PubMed Web of Science ®Google Scholar
• Bosch DE, Zielinski T, Lowery RG, Siderovski DP. Evaluating modulators of ‘Regulator of G-protein Signaling’ (RGS) proteins. Curr Protoc Pharmacol 2012;2:2.8
   Google Scholar
• Kimple AJ, Willard FS, Giguere PM, Johnston CA, Mocanu V, Siderovski DP. The RGS protein inhibitor CCG-4986 is a covalent modifier of the RGS4 Galpha-interaction face. Biochim Biophys Acta 2007;1774:1213–20
   PubMedGoogle Scholar
• Jang K-S, Paik SS, Chung H, Oh Y-H, Kong G. MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers. Cancer Sci 2006;97:374–9
   PubMed Web of Science ®Google Scholar
• Martin MD, Hilsenbeck SG, Mohsin SK, Hopp TA, Clark GM, Osborne CK, et al. Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat 2006;95:7–12
   PubMed Web of Science ®Google Scholar
• Kumar R, Wang RA, Mazumdar A, Talukder AH, Mandal M, Yang Z, et al. A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature 2002;418(6898):654–7
   PubMedGoogle Scholar
• Toh Y, Nicolson G. The role of the MTA family and their encoded proteins in human cancers: Molecular functions and clinical implications. Clin Exper Metastasis 2009;26:215–27
   PubMed Web of Science ®Google Scholar
• Li DQ, Pakala SB, Reddy SD, Ohshiro K, Peng SH, Lian Y, et al. Revelation of p53-independent function of MTA1 in DNA damage response via modulation of the p21 WAF1-proliferating cell nuclear antigen pathway. J Biol Chem 2010;285:10044–52
   PubMedGoogle Scholar
• Moon HE, Cheon H, Lee MS. Metastasis-associated protein 1 inhibits p53-induced apoptosis. Oncol Rep 2007;18:1311–14
   PubMedGoogle Scholar
• Yoo YG, Kong G, Lee MO. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO J. 2006;25:1231–41
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Cao Y, Li CY, Moeller B. Exploring the role of HIF-1 in early angiogenesis and response to radiotherapy. Radiother Oncol 2007;83:249–55
   PubMedGoogle Scholar
• Semenza GL. Oxygen sensing, homeostasis, and disease (author reply). N Engl J Med 2011;365:1845–6
   Google Scholar
• Amé JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004;26:882–93
   PubMed Web of Science ®Google Scholar
• Kim MY, Zhang T, Kraus WL. Poly(ADP-ribosyl)ation by PARP-1: ‘PAR-laying’ NAD+ into a nuclear signal. Genes Dev 2005;19:1951–67
   PubMed Web of Science ®Google Scholar
• Pyriochou A, Olah G, Deitch EA, Szabo C, Papapetropoulos A. Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34. Int J Mol Med 2008;22:113–18
   PubMed Web of Science ®Google Scholar
• Rajesh M, Mukhopadhyay P, Batkai S, Godlewski G, Hasko G, Liaudet L, et al. Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis. Biochem Biophys Res Commun 2006;350:352–7
   PubMed Web of Science ®Google Scholar
• Aust S, Obrist P, Klimpfinger M, Tucek G, Jager W, Thalhammer T. Altered expression of the hormone- and xenobiotic-metabolizing sulfotransferase enzymes 1A2 and 1C1 in malignant breast tissue. Int J Oncol 2005;26:1079–85
   PubMed Web of Science ®Google Scholar
• Wang Y, Spitz MR, Tsou AM, Zhang K, Makan N, Wu X. Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: A case-control analysis. Lung Cancer 2002;35:137–42
   PubMed Web of Science ®Google Scholar
• Falany JL, Falany CN. Interactions of the human cytosolic sulfotransferases and steroid sulfatase in the metabolism of tibolone and raloxifene. J Steroid Biochem Mol Biol 2007;107:202–10
   PubMed Web of Science ®Google Scholar
• Esmaili AM, Johnson EL, Thaivalappil SS, Kuhn HM, Kornbluth S, Irusta PM. Regulation of the ATM-activator protein AVEN by CRM1-dependent nuclear export. Cell Cycle 2010;9:3913–20
   PubMed Web of Science ®Google Scholar
• Chau BN, Cheng EH, Kerr DA, Hardwick JM. AVEN, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1. Mol Cell 2000;6:31–40
   PubMed Web of Science ®Google Scholar
• Choi J, Hwang YK, Sung KW, Kim DH, Yoo KH, Jung HL, et al. AVEN overexpression: Association with poor prognosis in childhood acute lymphoblastic leukemia. Leuk Res 2006;30:1019–25
   PubMed Web of Science ®Google Scholar
• Kluppel M. The roles of chondroitin-4-sulfotransferase-1 in development and disease. Prog Mol Biol Transl Sci 2010;93:113–32
   PubMedGoogle Scholar
• Jiang CP, Wu BH, Chen SP, Fu MY, Yang M, Liu F, et al. High COL4A3 expression correlates with poor prognosis after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Tumour Biol 2013;34:415–20
   PubMedGoogle Scholar
• Nie XC, Wang JP, Zhu W, Xu XY, Xing YN, Yu M, et al. COL4A3 expression correlates with pathogenesis, pathologic behaviors, and prognosis of gastric carcinomas. Hum Pathol 2013;44:77–86
   PubMedGoogle Scholar
• Georgiou GK, Igglezou M, Sainis I, Vareli K, Batsis H, Briasoulis E, et al. Impact of breast cancer surgery on angiogenesis circulating biomarkers: A prospective longitudinal study. World J Surg Oncol 2013;11:213 . PubMed PMID: 23981902. Epub 2013/08/29. Eng
   PubMedGoogle Scholar
• Jedeszko C, Sloane BF. Cysteine cathepsins in human cancer. Biol Chem 2004;385:1017–27
   PubMed Web of Science ®Google Scholar
• Ozawa K, Tsukamoto Y, Hori O, Kitao Y, Yanagi H, Stern DM, et al. Regulation of tumor angiogenesis by oxygen-regulated protein 150, an inducible endoplasmic reticulum chaperone. Cancer Res 2001;61:4206–13
   PubMed Web of Science ®Google Scholar
• Stojadinovic A, Hooke JA, Shriver CD, Nissan A, Kovatich AJ, Kao TC, et al. HYOU1/Orp150 expression in breast cancer. Med Sci Monit 2007;13:BR231–9
   PubMed Web of Science ®Google Scholar
• Tsukamoto Y, Kuwabara K, Hirota S, Kawano K, Yoshikawa K, Ozawa K, et al. Expression of the 150-kd oxygen-regulated protein in human breast cancer. Lab Invest 1998;78:699–706
   PubMedGoogle Scholar
• Lonne GK, Cornmark L, Zahirovic IO, Landberg G, Jirstrom K, Larsson C. PKCalpha expression is a marker for breast cancer aggressiveness. Mol Cancer 2010;9:76 . PubMed PMID: 20398285. Pubmed Central PMCID: PMC2873434. Epub 2010/04/20. eng
   PubMed Web of Science ®Google Scholar
• Jevnikar Z, Rojnik M, Jamnik P, Doljak B, Fonovic UP, Kos J. Cathepsin H mediates the processing of talin and regulates migration of prostate cancer cells. J Biol Chem 2013;288:2201–9
   PubMedGoogle Scholar
• Lawson C, Lim ST, Uryu S, Chen XL, Calderwood DA, Schlaepfer DD. FAK promotes recruitment of talin to nascent adhesions to control cell motility. J Cell Biol 2012;196:223–32
   PubMed Web of Science ®Google Scholar